Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Odyssey Thera Expand Cell-Based Drug-Profiling Collaboration

NEW YORK (GenomeWeb News) – Pfizer will use Odyssey Thera’s cell-based protein-fragment complementation assay (PCA) technology to evaluate the selectivity of Pfizer compounds, Odyssey said today.
 
Under the terms of the agreement, Odyssey will receive an upfront payment, research and capital expenditure funding, and success-based milestone payments. Further financial details were not disclosed.
 
The current research collaboration will focus on “large numbers” of Pfizer chemical leads and drug candidates from multiple therapeutic areas, Odyssey said. Odyssey and Pfizer will use the PCA technology and other assays based on automated microscopy to measure changes in cellular signaling networks in response to Pfizer compounds.
 

The agreement expands upon a May 2005 collaboration between the companies to profile certain Pfizer compounds using the PCA technology.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.